October 15, 2024

New Member: Welcome in our cluster to !LEVA Sciences GmbH

New Member: Welcome in our cluster to !LEVA Sciences GmbH
Go back

!LEVA specializes in guiding pharmaceutical companies through the complexities of development, from company foundation to early clinical studies. Over the past 25 years, the !LEVA management team has co-founded and successfully managed nearly a dozen companies, mainly in the pharmaceutical sector, while supporting numerous biotech companies in corporate and product development. !LEVA Sciences was founded to share this expertise with innovative life science projects, helping companies achieve success through hands-on involvement and C-level leadership when needed.

If you would like to learn more, please visit their Website.
Looking forward to your active participation!

Our latest News

discover more
Universität Heidelberg with 16 “Highly Cited Researchers”

Universität Heidelberg with 16 “Highly Cited Researchers”

International evaluation names researchers whose publications have been most cited worldwide 16 researchers from Heidelberg University feature on the recently published list of “Highly Cited Researchers”. This international evaluation names researchers whose publications have been cited most frequently worldwide in their respective field or who have an outstanding track-record of publications across several disciplines. The […]

read more
Universität Heidelberg: New DFG Research Unit in Oncology

Universität Heidelberg: New DFG Research Unit in Oncology

GenoMiCC consortium deals with functional genomics and microbiomics in colorectal cancer and is coordinated at the Medical Faculty Mannheim In the latest approval round of the German Research Foundation (DFG), Heidelberg University has been successful with a grant application for a new Research Unit in oncology. The GenoMiCC consortium pursues the goal of identifying new […]

read more
Merck and Promega collaborate on 3D cell technology for drug discovery

Merck and Promega collaborate on 3D cell technology for drug discovery

Full text in German below. Merck und Promega arbeiten gemeinsam an 3D-Zelltechnologie für die Wirkstoffforschung Strategische Partnerschaft bündelt Know-how von Merck im Bereich Organoide mit Promegas Assay-TechnologienForschende erhalten besseren und schnelleren Zugang zu krankheitsrelevanten ZellmodellenStärkt Mercks Position bei zukunftsweisenden Tools und Lösungen auf dem Gebiet der Biologie Darmstadt, Deutschland. (06. November 2025) Merck, ein führendes Wissenschafts- […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp